June 12, 2024
Asgard Therapeutics selects Exothera for clinical trials of its viral vector-based immunotherapy candidate
Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected…